Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history

Research output: Contribution to journalReviewResearchpeer-review


  1. Opening of ATP sensitive potassium channels causes migraine attacks with aura

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. PET imaging of meningioma with 18F-FLT: a predictor of tumour progression

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Functional gene networks reveal distinct mechanisms segregating in migraine families

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Effects of Exo- and Endocannabinoids in Multiple Sclerosis

    Research output: Book/ReportPh.D. thesis

View graph of relations

In the past decade, changes have occurred in the spectrum of multiple sclerosis courses. The natural history of multiple sclerosis appears milder from the first sign of demyelinating disease to the progressive course, probably as a result of an interplay between several factors including changes in the diagnostic criteria, changes in the epidemiology of multiple sclerosis, impact of early and appropriate disease-modifying treatment and improvement of the general state of health in the population. It has been suggested to regard incidental findings of demyelinating lesions in MRI in individuals without any history of clinical symptoms consistent with neurological dysfunction, so-called radiological isolated syndrome, as the initial course of multiple sclerosis. New diagnostic criteria have enabled the multiple sclerosis diagnosis in many patients at the first clinical demyelinating event, clinically isolated syndrome. The remaining patients with clinically isolated syndrome have a more benign prognosis, and for relapsing-remitting multiple sclerosis, the prognosis has become more favourable. Reduced disease activity in patients with relapsing-remitting multiple sclerosis can partly be ascribed to more efficacious new disease-modifying therapies but decrease in disease activity has also be seen in placebo-treated patients in clinical trials. This may be explained by several factors: change in the diagnostic criteria, more explicit inclusion criteria, exclusion of high-risk patients e.g. patients with co-morbidities, and more rigorous definitions of relapses and disease worsening. However, these factors also make the disease course in patients treated with disease-modifying therapies seem more favourable. In addition, change in the therapeutic target to stable disease (no evidence of disease activity = no relapses, no disease worsening and no MRI activity) could by itself change the course in relapsing-remitting multiple sclerosis. The effectiveness of disease-modifying drugs has reduced the transition from relapsing-remitting to secondary progressive multiple sclerosis. The concept of progressive multiple sclerosis has also evolved from two very distinct categories (primary progressive and secondary progressive multiple sclerosis) to a unified category of progressive multiple sclerosis, which can then be split into the categories of active or inactive. Also, an increasing tendency to treat progressive multiple sclerosis with disease-modifying therapies may have contributed to change the course in progressive multiple sclerosis. In conclusion, during the past decade the entire course of multiple sclerosis from the first sign of a demyelinating disorder through the progressive course appears to be milder due to a complex interplay of several factors.

Original languageEnglish
Issue number9
Pages (from-to)2637-2652
Number of pages16
Publication statusPublished - 1 Sep 2020

    Research areas

  • multiple sclerosis, clinically isolated syndrome, epidemiology, imaging, biomarkers

ID: 61519730